ASH 2024 Insights: Secondary Heme Malignancies in Myeloma Post-CAR-T Therapy - Prevalence and Mutational Landscape

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Find latest Myeloma videos · 500+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

This video is featured in the 2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Secondary Heme Malignancies in Myeloma Post-CAR-T Therapy - Prevalence and Mutational Landscape

By 2024 ASH Annual Meeting Insights Hub FEATURING Johannes Waldschmidt

111 views

December 31, 2024

Comments 0

Insights on Proteasome Inhibitor Combinations at First Relapse in Mu…

Feat. M. Levy

2024 ASH Annual Meeting Insights Hub: Myeloma Videos

New

ASH 2024 Insights: Upfront Use of Anti-CD38 Monoclonal Antibodies in…

2024 ASH Annual Meeting Insights Hub

A. Khan

63 views

ASH 2024 Insights: Association of Pre-Treatment Biomarkers With Toxi…

2024 ASH Annual Meeting Insights Hub

D. Hansen

40 views

ASH 2024 Insights: Belamaf Monotherapy in Pts With R/R Light Chain A…

2024 ASH Annual Meeting Insights Hub

E. Kastritis

36 views

View All

ASH 2024 Summary: Myeloma Highlights and Impact on Practice

2024 ASH Annual Meeting Insights Hub

H. Hashmi

1.3K views

ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

1.3K views

ASH 2024 Review: Key Multiple Myeloma Abstracts

Cleveland Clinic Taussig Cancer Institute

N. Callander

429 views

ASH 2024 Summary: Multiple Myeloma Highlights and Clinical Implicati…

2024 ASH Annual Meeting Insights Hub

S. Al Hadidi

455 views

BPDCN: A Dermatologist's Perspective on Differential Diagnosis

Jesse Hirner

1.7K views

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

4.8K views

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

790 views

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

369 views

ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid D…

2024 ASH Annual Meeting Insights Hub

H. Fernandez

258 views

Debate: Using BCMA CAR-T in Early vs Late Line R/R MM Treatment

Louisville Hematology Highlights

K. Patel, S. Usmani

178 views

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

394 views

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

827 views

ASH 2024 Summary: Transplant in Myeloma - Key Factors in Decision-Ma…

2024 ASH Annual Meeting Insights Hub

A. Perrot

179 views

Real-World Characteristics and Outcomes in Patients With RRMM Receiv…

Adeel Khan

141 views

ASH 2024 Review: Updates on the Management of MDS

Cleveland Clinic Taussig Cancer Institute

H. Carraway

140 views

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

485 views

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

588 views

CAR-T Strategies and Clinical Considerations for R/R MM

Moffitt Cancer Center

K. Patel

151 views

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

1.3K views

Debate: There Is a Role for Anti-Inflammatory Treatment in MDS

MDS Foundation

L. Weeks

108 views

AUTOPLAY

Login

Login

Join VuMedi

ASH 2024 Insights: Secondary Heme Malignancies in Myeloma Post-CAR-T Therapy - Prevalence and Mutational Landscape

Insights on Proteasome Inhibitor Combinations at First Relapse in Mu…

2024 ASH Annual Meeting Insights Hub: Myeloma Videos

ASH 2024 Insights: Upfront Use of Anti-CD38 Monoclonal Antibodies in…

ASH 2024 Insights: Association of Pre-Treatment Biomarkers With Toxi…

ASH 2024 Insights: Belamaf Monotherapy in Pts With R/R Light Chain A…

Related Videos

ASH 2024 Summary: Myeloma Highlights and Impact on Practice

ASH 2024 Summary: Highlights in AML, MDS, and ALL

ASH 2024 Review: Key Multiple Myeloma Abstracts

ASH 2024 Summary: Multiple Myeloma Highlights and Clinical Implicati…

BPDCN: A Dermatologist's Perspective on Differential Diagnosis

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid D…

Debate: Using BCMA CAR-T in Early vs Late Line R/R MM Treatment

Myeloid Malignancies: Hot Topics in 2024

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

ASH 2024 Summary: Transplant in Myeloma - Key Factors in Decision-Ma…

Real-World Characteristics and Outcomes in Patients With RRMM Receiv…

ASH 2024 Review: Updates on the Management of MDS

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

ESMO 2024 Summary: Highlights in Heme Malignancies

CAR-T Strategies and Clinical Considerations for R/R MM

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Debate: There Is a Role for Anti-Inflammatory Treatment in MDS